Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
8.03
-0.35 (-4.18%)
At close: Oct 23, 2026, 4:00 PM EDT
8.02
-0.01 (-0.12%)
After-hours: Oct 23, 2026, 7:59 PM EDT
Candel Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
55
Market Cap
614.44M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 125.00K | - | - |
| Dec 31, 2021 | 125.00K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 462.25M |
| Zevra Therapeutics | 136.07M |
| Ginkgo Bioworks Holdings | 132.42M |
| Gyre Therapeutics | 109.82M |
| Wave Life Sciences | 65.37M |
| Prime Medicine | 4.07M |
| Attovia Therapeutics | 1.80M |
CADL News
- 2 days ago - Candel Therapeutics Appoints Maria Ostrovsky as General Counsel - GlobeNewsWire
- 2 days ago - Candel Therapeutics initiated with a Buy at Jefferies - TheFly
- 22 days ago - Candel Therapeutics to Present at the SITC 2026 Annual Meeting - GlobeNewsWire
- 23 days ago - Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 23 days ago - Candel announces final phase 2a trial of aglatimagene, valacyclovir - TheFly
- 23 days ago - Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI - GlobeNewsWire
- 24 days ago - Candel Therapeutics announces data from phase 2 PrTK05 trial - TheFly
- 24 days ago - Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer - GlobeNewsWire